1 DECLARE study design DECLARE was a randomized, double-blind, placebo-controlled, multicenter trial (N=17,160) designed to evaluate the effect of FARXIGA 10 mg compared with placebo on CV outcomes in adults with T2D and either multiple CV risk factors (n=10,186) or eCVD (n=6,974)
Experts say that in a similar way to other weight loss techniques, someone taking Ozempic or Wegovy (with active ingredient semaglutide) will eventually stop shedding pounds and their body will settle at a certain weight, which may not be the individuals target weight
Tirzepatide is administered once weekly, making the dosing schedule convenient for both
The drinks are packed with protein (20 to 61 grams) and fiber (2 to 15 grams)
However, under conditions of iron overload, excess Fe 2+ in the LIP undergoes Fenton chemistry with H 2 O 2 , producing excessive ROS, promoting lipid peroxidation, and ultimately triggering ferroptosis (Zhao et al., 2025a)
If youve been researching newer GLP-1 medications or advanced peptide therapies for weight loss, youve probably seen people comparing these two options and asking the same question: Which one actually works better
